XtalPi

paid

XtalPi combines AI, quantum physics, and robotic automation to accelerate molecular R&D for pharma, new materials, and energy industries. Explore autonomous labs, AI molecular design, and drug development solutions.

AI Models & Infrastructure

Research & Education

AI Research Tools

About

XtalPi (晶泰科技) is an advanced AI and robotics technology company that has built a next-generation intelligent R&D platform for molecular science. By integrating quantum physics, proprietary AI models trained on domain-specific data, cloud computing, and laboratory robotics, XtalPi enables high-throughput, high-quality closed-loop experimentation across industries including biopharmaceuticals, new materials, petrochemicals, and new energy. The platform's core pillars include AI Autonomous Laboratories, AI Molecular Design, Small Molecule Drug Development, and Drug Solid Form Research. Its AI software suite features PatSight (pharmaceutical patent mining), XFEP (free energy perturbation for binding affinity prediction), and XMolGen (generative chemistry for molecular design). On the hardware side, XtalPi offers the XmartChem® intelligent synthesis workstation, XtalComplete® intelligent crystallization station, and ChemPlus® desktop solid sampler. For drug discovery, XtalPi supports the full pipeline from hit identification and lead optimization through DMTA cycles and structural biology to pre-clinical candidate development. The Xtalgazer® platform specifically accelerates drug solid-state research through crystal form prediction, crystallization strategy recommendation, and automated experimentation. XtalPi is designed for enterprise pharmaceutical companies, biotech startups, material science research institutes, and energy chemical corporations looking to radically accelerate R&D timelines with AI-powered, robot-executed workflows.

Key Features

AI Autonomous Laboratory: Integrates AI algorithms, robotic automation, and digital platforms to create smart, high-throughput R&D labs across pharma, materials, and energy sectors.
AI Molecular Design Suite: Includes PatSight for patent mining, XFEP for free energy perturbation binding affinity prediction, and XMolGen for generative molecular design to identify novel drug candidates.
Small Molecule Drug Development: Supports end-to-end small molecule drug discovery from hit identification and lead optimization through DMTA cycles and structural biology to pre-clinical candidates.
Xtalgazer® Drug Solid Form Platform: AI-powered platform for crystal form and salt/co-crystal screening, crystal structure analysis, crystallization strategy recommendation, and solid dispersion formulation.
Intelligent Laboratory Hardware: Proprietary hardware including XmartChem® synthesis workstations, XtalComplete® crystallization stations, and ChemPlus® solid samplers for precision automated experimentation.

Use Cases

Pharmaceutical companies using AI molecular design to rapidly screen and identify novel small molecule drug candidates from vast chemical spaces.
Biotech firms leveraging XtalPi's autonomous robotic labs to run high-throughput DMTA cycles and accelerate lead optimization without expanding wet lab headcount.
Drug formulators using the Xtalgazer® platform to predict optimal crystal forms, salts, and co-crystals for drug stability and bioavailability optimization.
Materials science and energy companies deploying XtalPi's AI and robotics infrastructure to discover new functional materials and electrolyte compositions.
R&D organizations using PatSight to mine pharmaceutical patents for competitive intelligence and identify white-space opportunities in chemical IP landscapes.

Pros

Full-Stack R&D Platform: Covers software, hardware, and services in a single integrated ecosystem, supporting the entire molecular research lifecycle from design to pre-clinical development.
Closed-Loop AI + Robotics Iteration: Automated robotic experiments feed high-quality data back into AI models, enabling continuous learning and rapid iteration that dramatically shortens discovery timelines.
Multi-Industry Applicability: Beyond pharma, XtalPi's platform extends to new materials, petrochemicals, and new energy sectors, making it versatile for a wide range of molecular R&D needs.
Proprietary Quantum-Physics-Based AI Models: Models trained on domain-specific, high-quality datasets with quantum physics foundations deliver high-accuracy predictions for molecular properties and solid-state behavior.

Cons

Enterprise-Focused Pricing: XtalPi is positioned as an enterprise solution with no publicly available self-serve or free tier, making it inaccessible for independent researchers or small academic labs.
Primarily Chinese-Language Interface: Much of the platform documentation, marketing, and support resources are in Mandarin Chinese, which may present a barrier for non-Chinese-speaking international users.
High Implementation Complexity: Deploying and integrating the full suite of AI software, robotic hardware, and digital platforms requires significant organizational investment and technical expertise.

Frequently Asked Questions

XtalPi primarily serves the biopharmaceutical industry for drug discovery and development, but its AI and robotics platform also extends to new materials science, petrochemicals, and new energy sectors.

XtalPi offers PatSight for pharmaceutical patent extraction and analysis, XFEP for high-accuracy free energy perturbation binding affinity calculations, and XMolGen for generative molecular design and multi-functional compound exploration.

The AI Autonomous Laboratory integrates AI-driven experimental planning, robotic execution of chemical experiments, and digital data governance into a closed-loop system that continuously improves through high-throughput data collection and AI model retraining.

Xtalgazer® is XtalPi's dedicated drug solid-state research platform. It uses AI-driven crystal form prediction, automated crystallization experiments, crystal structure analysis, and solid dispersion formulation development to accelerate drug solid-form R&D.

Yes, XtalPi offers end-to-end drug discovery services for small molecules and antibodies, including hit discovery, lead optimization, structural biology, DMTA cycles, and pre-clinical candidate development in collaboration with partners.